Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Anti‐depressants and centrally active agents for fibromyalgia syndrome

Information

DOI:
https://doi.org/10.1002/14651858.CD006192Copy DOI
Database:
  1. Cochrane Database of Systematic Reviews
Version published:
  1. 18 October 2006see what's new
Type:
  1. Intervention
Stage:
  1. Protocol
Cochrane Editorial Group:

  1. Cochrane Musculoskeletal Group

Copyright:
  1. Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Article metrics

Altmetric:

Cited by:

Cited 0 times via Crossref Cited-by Linking

Collapse

Authors

  • María Betina Nishishinya

    Correspondence to: Iberoamerican Cochrane Centre, Institute of Biomedical Research (IIB Sant Pau), Barcelona, Spain

    [email protected]

    [email protected]

  • Brian Walitt

    Georgetown University Medical Center, Washington Hospital Center, Washington, USA

  • Gerard Urrútia

    Iberoamerican Cochrane Centre ‐ IIB Sant Pau, CIBER Epidemiología y Salud Pública (CIBERESP), Spain, Barcelona, Spain

  • Philip J Mease

    Rheumatology Clinical Research, Swedish Hospital Medical Center, Seattle, USA

  • Alexis Rodríguez

    Servei de Farmacologia, Hospital de la Vall d'Hebron, Barcelona, Spain

  • Ricardo J Riera Lizardo

    Medicine Department, Rheumatology Unit, Universidad de Carabobo, Valencia, Venezuela

  • Luis Ernesto González

    Facultad de Ciencias de la Salud Eugenio Espejo, Universidad Tecnológica Equinoccial, Quito, Ecuador

  • Godwin Darko

    Department of Medicine, Washington Hospital Center, Washington, USA

Contributions of authors

RR wrote a previous version of a similar protocol ('Specific serotonin uptake inhibitors versus placebo or antidepressants for fibromyalgia') which was the base to develop this current protocol. That previous protocol has been withdrawn and included in this much broader review.

BN and GU wrote the current version of this protocol.

BW extensively reviewed the protocol and suggested amendments from the clinical perspective. He also provided a description of how it is expected that the interventions may work.

PM initially act as an external peer reviewer of this protocol making valuable suggestions that helped much to improve it. As a renowned expert in this field, he was invited to join the team of authors for this review.

Sources of support

Internal sources

  • Iberoamerican Cochrane Center, Spain.

External sources

  • Agencia d'Avaluació de Tecnologia i Recerca Mèdiques (146/24/2004), Spain.

Declarations of interest

None declared

Version history

Published

Title

Stage

Authors

Version

2006 Oct 18

Anti‐depressants and centrally active agents for fibromyalgia syndrome

Protocol

María Betina Nishishinya, Brian Walitt, Gerard Urrútia, Philip J Mease, Alexis Rodríguez, Ricardo J Riera Lizardo, Luis Ernesto González, Godwin Darko

https://doi.org/10.1002/14651858.CD006192

Notes

This is the generic protocol for seven reviews:

  • Anticonvulsants for fibromyalgia syndrome

  • Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome

  • NSAIDs, analgesics and opioid agents for fibromyalgia syndrome

  • Sedatives and hypnotic agents for fibromyalgia syndrome

  • Selective serotonin reuptake inhibitors for fibromyalgia syndrome

  • Serotonin and noradrenaline reuptake inhibitors (SNRI) for fibromyalgia syndrome

  • Tricyclic agents for fibromyalgia syndrome

The protocol will be published until all seven reviews are completed.